BR112012000660A2 - compostos heterociclos e seus usos - Google Patents
compostos heterociclos e seus usosInfo
- Publication number
- BR112012000660A2 BR112012000660A2 BR112012000660A BR112012000660A BR112012000660A2 BR 112012000660 A2 BR112012000660 A2 BR 112012000660A2 BR 112012000660 A BR112012000660 A BR 112012000660A BR 112012000660 A BR112012000660 A BR 112012000660A BR 112012000660 A2 BR112012000660 A2 BR 112012000660A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterocycle compounds
- heterocycle
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22025909P | 2009-06-25 | 2009-06-25 | |
PCT/US2010/040027 WO2010151791A1 (en) | 2009-06-25 | 2010-06-25 | Heterocyclic compounds and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012000660A2 true BR112012000660A2 (pt) | 2016-11-16 |
Family
ID=42776992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012000660A BR112012000660A2 (pt) | 2009-06-25 | 2010-06-25 | compostos heterociclos e seus usos |
Country Status (18)
Country | Link |
---|---|
US (1) | US8940724B2 (pt) |
EP (1) | EP2445886B1 (pt) |
JP (1) | JP2012531438A (pt) |
KR (1) | KR20140015121A (pt) |
CN (1) | CN102625799A (pt) |
AR (1) | AR077254A1 (pt) |
AU (1) | AU2010265932B2 (pt) |
BR (1) | BR112012000660A2 (pt) |
CA (1) | CA2765823A1 (pt) |
CL (1) | CL2011003297A1 (pt) |
EA (1) | EA201270051A1 (pt) |
IL (1) | IL216973A0 (pt) |
MX (1) | MX2011013666A (pt) |
SG (1) | SG176978A1 (pt) |
TW (1) | TW201111376A (pt) |
UY (1) | UY32742A (pt) |
WO (1) | WO2010151791A1 (pt) |
ZA (1) | ZA201200613B (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009155121A2 (en) * | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
JP5712524B2 (ja) * | 2009-10-28 | 2015-05-07 | Jsr株式会社 | 液晶配向剤および液晶表示素子 |
US8987301B2 (en) | 2009-11-07 | 2015-03-24 | Merck Patent Gmbh | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors |
ES2528441T3 (es) * | 2010-02-22 | 2015-02-10 | Merck Patent Gmbh | Hetarilaminonaftiridinas |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
FR2961206B1 (fr) * | 2010-06-09 | 2012-07-20 | Rhodia Operations | Procede de preparation de composes esteramides |
JP2013533883A (ja) * | 2010-06-30 | 2013-08-29 | アムジエン・インコーポレーテツド | PI3Kδ阻害剤としての含窒素複素環化合物 |
EP2588471A1 (en) * | 2010-06-30 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
WO2012034116A2 (en) * | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2012135160A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
KR20130016041A (ko) * | 2011-08-04 | 2013-02-14 | 재단법인 의약바이오컨버젼스연구단 | 신규한 아닐린 유도체 및 이의 용도 |
CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
EP2875015A1 (en) * | 2012-07-23 | 2015-05-27 | Merck Patent GmbH | Ligands and their preparation |
CN104870017B (zh) | 2012-11-08 | 2020-08-14 | 理森制药股份公司 | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
EP3632426A1 (en) | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
MX362896B (es) | 2013-02-19 | 2019-02-22 | Amgen Inc | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |
JP6377123B2 (ja) | 2013-03-14 | 2018-08-22 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としてのヘテロアリール酸モルホリノン化合物 |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
EP4039256A1 (en) | 2013-11-11 | 2022-08-10 | Amgen Inc. | Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia |
AU2015276537B2 (en) * | 2014-06-16 | 2019-03-14 | Fundacion Para La Investigacion Medica Aplicada | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
WO2016001855A1 (en) | 2014-07-04 | 2016-01-07 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
CN106008479B (zh) | 2015-03-06 | 2020-01-10 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 |
PE20180783A1 (es) * | 2015-08-07 | 2018-05-07 | Bayer Cropscience Ag | Derivados heterociclicos condensados sustituidos por 2-(het) arilo como pesticidas |
EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES |
US10544113B2 (en) | 2016-03-07 | 2020-01-28 | National Health Research Institute | Thiazolidinone compounds and use thereof |
GB201604969D0 (en) * | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
MX2019013862A (es) | 2017-05-23 | 2020-01-20 | Mei Pharma Inc | Terapia de combinacion. |
MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
JP2020533317A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド | 特異的akt3活性化剤およびその使用 |
CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
CN111018777B (zh) * | 2019-11-25 | 2021-02-12 | 武汉智顿科技发展有限公司 | 一种地喹氯铵的制备方法 |
CN110963967B (zh) * | 2019-11-25 | 2021-02-12 | 武汉智顿科技发展有限公司 | 一种2-甲基-4-氨基喹啉的制备方法 |
US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
KR20230158659A (ko) * | 2021-03-18 | 2023-11-21 | 쑤저우 궈쾅 팜테크 코포레이션 리미티드 | Ctla-4 소분자 분해제 및 그 응용 |
CN113277978B (zh) * | 2021-06-02 | 2022-06-03 | 河南师范大学 | 一种2,4-双取代喹啉类化合物的制备方法 |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3823147A (en) * | 1968-05-24 | 1974-07-09 | Hoechst Ag | Thiophenyl-substituted quinophthalone dispersion dyestuffs |
US3655672A (en) * | 1968-05-24 | 1972-04-11 | Hoechst Ag | Quinophthalone dyestuffs and process for preparing them |
DE2025288A1 (de) * | 1970-05-23 | 1971-12-09 | Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt | Dispersionsfarbstoffe der Chinophthalonreihe und Verfahren zu deren Herstellung |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
WO1992017452A1 (en) | 1991-04-03 | 1992-10-15 | Korea Research Institute Of Chemical Technology | 2-quinolinone derivatives |
US5296445A (en) * | 1991-08-06 | 1994-03-22 | Mitsui Toatsu Chemicals, Incorporated | Dye for heat-sensitive transfer record, ink composition for heat-sensitive transfer record, and transfer sheet |
JP3347779B2 (ja) * | 1991-11-14 | 2002-11-20 | 大日本印刷株式会社 | 熱転写シート |
GB9312891D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
AU3088799A (en) * | 1998-03-18 | 1999-10-11 | Humanetics Corporation | Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents |
DE60009888T2 (de) * | 1999-04-21 | 2005-04-21 | Wyeth Corp | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen |
US6355636B1 (en) * | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
JP2003526686A (ja) | 2000-03-13 | 2003-09-09 | アメリカン・サイアナミド・カンパニー | 結腸ポリープの治療または阻害するためのシアノキノリンの使用 |
WO2004069250A1 (en) | 2003-02-03 | 2004-08-19 | Astrazeneca Ab | 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors |
WO2004108704A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours |
WO2004108703A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinyl 3-cyanoquinoline derivatives for use in the treatment of tumours |
EP1633718B1 (en) | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
CA2599992A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
CA2608540A1 (en) * | 2005-05-18 | 2006-11-23 | Wyeth | 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same |
TW200829555A (en) | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
EP2139882B1 (en) * | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
GB0821693D0 (en) | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
-
2010
- 2010-06-25 EA EA201270051A patent/EA201270051A1/ru unknown
- 2010-06-25 KR KR1020127001738A patent/KR20140015121A/ko not_active Application Discontinuation
- 2010-06-25 MX MX2011013666A patent/MX2011013666A/es not_active Application Discontinuation
- 2010-06-25 CA CA2765823A patent/CA2765823A1/en not_active Abandoned
- 2010-06-25 UY UY0001032742A patent/UY32742A/es not_active Application Discontinuation
- 2010-06-25 JP JP2012517779A patent/JP2012531438A/ja active Pending
- 2010-06-25 WO PCT/US2010/040027 patent/WO2010151791A1/en active Application Filing
- 2010-06-25 EP EP10729753.3A patent/EP2445886B1/en active Active
- 2010-06-25 BR BR112012000660A patent/BR112012000660A2/pt not_active IP Right Cessation
- 2010-06-25 AR ARP100102284A patent/AR077254A1/es not_active Application Discontinuation
- 2010-06-25 US US12/823,767 patent/US8940724B2/en active Active
- 2010-06-25 CN CN2010800385536A patent/CN102625799A/zh active Pending
- 2010-06-25 SG SG2011095825A patent/SG176978A1/en unknown
- 2010-06-25 TW TW099120993A patent/TW201111376A/zh unknown
- 2010-06-25 AU AU2010265932A patent/AU2010265932B2/en not_active Expired - Fee Related
-
2011
- 2011-12-14 IL IL216973A patent/IL216973A0/en unknown
- 2011-12-23 CL CL2011003297A patent/CL2011003297A1/es unknown
-
2012
- 2012-01-25 ZA ZA2012/00613A patent/ZA201200613B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201200613B (en) | 2012-10-31 |
JP2012531438A (ja) | 2012-12-10 |
IL216973A0 (en) | 2012-02-29 |
AU2010265932B2 (en) | 2014-11-20 |
AR077254A1 (es) | 2011-08-10 |
CA2765823A1 (en) | 2010-12-29 |
AU2010265932A1 (en) | 2012-01-19 |
SG176978A1 (en) | 2012-02-28 |
US20100331293A1 (en) | 2010-12-30 |
CN102625799A (zh) | 2012-08-01 |
TW201111376A (en) | 2011-04-01 |
EP2445886A1 (en) | 2012-05-02 |
EP2445886B1 (en) | 2016-03-30 |
KR20140015121A (ko) | 2014-02-06 |
EA201270051A1 (ru) | 2012-05-30 |
US8940724B2 (en) | 2015-01-27 |
WO2010151791A1 (en) | 2010-12-29 |
CL2011003297A1 (es) | 2012-06-15 |
UY32742A (es) | 2010-12-31 |
MX2011013666A (es) | 2012-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012000660A2 (pt) | compostos heterociclos e seus usos | |
BRPI1016150A2 (pt) | compostos heterocíclicos e seus usos. | |
BR112013006272A2 (pt) | compostos de piridina e seus usos | |
BR112012003709A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BRPI0910746A2 (pt) | reticuladores e seus usos | |
BRPI0817881A2 (pt) | Compostos orgânicos e seus usos | |
BR112013005523A2 (pt) | composto como inibidores de quinase c-met e seus usos | |
BR112013012190A2 (pt) | composições adesivas e seus usos | |
BRPI0909185A2 (pt) | Derivado de vitamina e e seus usos | |
BRPI1008082A2 (pt) | Isotiazoliloxifenilamisinas e seu emprego como fungicidas | |
BR112012002114A2 (pt) | cevadas e seu usos. | |
BRPI0908853A2 (pt) | composto oligopeptídicos e seus usos | |
BR112013012129A2 (pt) | composições de adesivos e seus usos | |
BRPI0921862A2 (pt) | inibidores de raf e seus usos | |
DK2246017T3 (da) | Absorberende genstand | |
BR112012005016A2 (pt) | artigo absorvente | |
BRPI1010239A2 (pt) | endoglucanases aprimoradas, derivados e seus usos | |
BRPI1008299A2 (pt) | artigo absorvente | |
BRPI1016067A2 (pt) | ésteres e seus usos. | |
BR112013008898A2 (pt) | benzamidas substituídas e seus usos | |
BR112013033919A2 (pt) | combinações e seus usos | |
BRPI1006506A2 (pt) | artigo absorvente | |
DK2279652T3 (da) | Kultivator | |
BR112012003970A2 (pt) | N-alcoxicarboxamidas e seu uso como microbicidas | |
BRPI0821138A2 (pt) | Aminotiazóis e seus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |